In 2023, Pablo Legorreta earned $84.84M in total compensation at Royalty Pharma. Most recently acquired 130,000 shares in Jun 2023. Currently holds stock worth $113.98M. 5+ years at the helm of Royalty Pharma.
Compensation History
Annual executive compensation data for Pablo Legorreta, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$84.84M
Salary
$0.00
Bonus
$0.00
Other
$84.84M
Salary
$0.00Board Justification
The compensation philosophy emphasizes alignment with shareholder interests and long-term performance, with a focus on attracting and retaining top talent through performance-based compensation.
Bonus
$0.00Board Justification
Mr. Legorreta does not participate in our annual cash bonus plan.
Other Compensation
$84.84MBoard Justification
Mr. Legorreta is entitled to certain profits of the Manager, which consist of the management fee from Royalty Pharma less the expenses of the Manager, including operating expenses and the compensation of the employees of the Manager.
Restricted Stock
Board Justification
Mr. Legorreta is entitled to Equity Performance Awards but does not receive employee compensation for his services.
Performance Metrics
The performance metrics for Mr. Legorreta's compensation are tied to the profits of the Manager and the overall performance of Royalty Pharma.
Pablo Legorreta
Founder and CEO of Royalty Pharma
Education
MBA from Columbia Business School
Field of Expertise
Finance & Banking - Finance
Sector of Economy
Healthcare
Born
April 1, 1963 - 62 years ago
CEO of Royalty Pharma for
5 years 5 months (Jun 2020 - Present)
Previous Experience
Founder of Royalty Pharma
Holdings
Track Pablo Legorreta's stock holdings and portfolio value over time.
Insider Trading
Pablo Legorreta's recent stock transactions, purchases, and sales filed with the SEC.
$3.84M
RPRX at $29.51/share
Jun 28, 2023
Purchase
$2.96M
RPRX at $32.89/share
Jun 12, 2023
Purchase
$4.84M
RPRX at $32.25/share
May 24, 2023
Purchase
$7.65M
RPRX at $33.25/share
May 16, 2023
Purchase
292,190.49 shares
RPRX
Dec 30, 2022
Charity
$560.00K
RPRX at $28.00/share
Jun 15, 2020
Purchase
Rivals
Compare Pablo Legorreta with competitor CEOs and industry peers.